Intravenous immunoglobulin G in the treatment of autoimmune bullous disease

Czernik, Annette

doi:10.1111/cei.12535

Search citation statements

Order By: Relevance

Paper Sections

Select...

Nonatopic Dermatologic Disorders1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2022

Publication Types

Select...

Book2

Article1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients refractory to IVIG and immunosuppressant, rituximab has been added, but its role in immunobullous disease requires further evaluation. 521 Toxic epidermal necrolysis and Stevens-Johnson syndrome. Toxic epidermal necrolysis and Stevens-Johnson syndrome are potentially fatal disorders.…”

Section: Nonatopic Dermatologic Disordersmentioning

confidence: 99%

Update on the use of immunoglobulin in human disease: A review of evidence

Perez

Orange

Bonilla

et al. 2017

Journal of Allergy and Clinical Immunology

483

462

View full text Add to dashboard Cite

Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted.

show abstract

Section: Nonatopic Dermatologic Disordersmentioning

confidence: 99%